ArticleMedical oncology (Northwood, London, England)2025
Bit1 promotes the progression of gastric cancer by facilitating epithelial-mesenchymal transition and alleviating apoptosis.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Gastric cancer remains the fifth most common malignant cancer all around the world, in 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Surgery and chemotherapy are the ways for non-early gastric cancer. Thus, it is particularly important to identify new biomarkers. The Bcl-2 inhibitor of transcription 1 (Bit1) is a mitochondrial apoptotic effector molecule, and involved in the cancer development with EMT, such as ovarian, oral, and esophageal cancers. In the present study, Bit1 was detected firstly, then clinicopathological parameters of the patients and survival time related to Bit1 were also analyzed. The relationship between Bit1 and risk factors for gastric cancer was analyzed by bioinformatics. Subsequently, lentivirus transfection was used to knockdown Bit1, and the effects of Bit1 on the proliferation, migration, and apoptosis of gastric cancer cells were detected, the process of EMT was also further observed. Our study demonstrated the higher expression of Bit1 in patients with primary gastric cancer, while Bit1 knockdown reduced gastric cancer cell proliferation, promoted cell apoptosis and mitochondrial injury, and restricted the metastasis of cancer cells by inhibiting the EMT process. Our results showed that Bit1 promoted the progression of gastric cancer, which afforded a novel biomarker and intervention target for gastric cancer.
Indexed as
Identifiers
40455389What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.